Kopran Limited — Important, 14-11-2024: Updates

**Financial Highlights:** Kopran reported a revenue from operations of ₹15,156 lakh for Q2 FY 2024-25, showing an increase from ₹13,944 lakh in Q1 FY 2024-25 but a slight decline compared to ₹15,259 lakh in Q2 FY 2023-24. The company’s EBITDA was ₹1,474 lakh, resulting in an EBITDA margin of 9.72%. Net profit stood at ₹738 lakh, down from ₹1,110 lakh in the previous quarter and ₹1,377 lakh in Q2 FY 2023-24.

**Strategic Initiatives and Growth Drivers:** Kopran is focused on enhancing its research and development capabilities, aiming to develop niche and high-value APIs. The company plans to expand its capacity and improve compliance with global regulatory standards.

**Business Developments:** The operational performance highlights indicate a diverse API portfolio, with notable strengths in anti-diabetic and anti-infective segments. The company's strategic initiatives may position it favorably for future opportunities.

**Market Position and Competitive Advantage:** With over 50 nations in its export reach, Kopran benefits from a robust manufacturing infrastructure that meets international quality standards, maintaining a competitive edge in both regulated and non-regulated markets.

**Investor Implications:** Given the improved EBITDA margins and ongoing strategic initiatives, there is a positive outlook for Kopran. Investors should watch closely as the company navigates its growth trajectory, focusing on both profitability and future expansions.